GSK2881078

a selective androgen receptor modulator that induces anabolic effects in muscle

Also Known As:

(R)-1-(1-(methylsulfonyl)propan-2-yl)-4-(trifluoromethyl)-1H-indole-5-carbonitrile; GSK-2881078

Networked: 2 relevant articles (0 outcomes, 1 trials/studies)

1.	Chronic Obstructive Pulmonary Disease (COPD) 01/01/2023 - "This phase 2A trial investigated the effects of a SARM, GSK2881078, in conjunction with exercise, on leg strength in patients with chronic obstructive pulmonary disease (COPD) and impaired physical function. " 01/01/2023 - "GSK2881078 was well tolerated and short-term treatment increased leg strength, when expressed as per cent predicted, in men with COPD more than physical training alone. "
2.	Rhabdomyolysis 05/10/2023 - "Two individuals exposed to GSK2881078 in a clinical trial were reported to have rhabdomyolysis. "